[go: up one dir, main page]

WO2002003061A3 - Verfahren zur identifizierung von die für behandlung von virusinfektionen geeigneten stoffen - Google Patents

Verfahren zur identifizierung von die für behandlung von virusinfektionen geeigneten stoffen Download PDF

Info

Publication number
WO2002003061A3
WO2002003061A3 PCT/EP2001/007781 EP0107781W WO0203061A3 WO 2002003061 A3 WO2002003061 A3 WO 2002003061A3 EP 0107781 W EP0107781 W EP 0107781W WO 0203061 A3 WO0203061 A3 WO 0203061A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus infections
treating virus
identifying substances
substances
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007781
Other languages
English (en)
French (fr)
Other versions
WO2002003061A2 (de
Inventor
Christoph Braeuchle
Georg Seisenberger
Martin Ried
Thomas Endress
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP01955335A priority Critical patent/EP1297183A2/de
Priority to CA002414786A priority patent/CA2414786A1/en
Priority to AU2001277528A priority patent/AU2001277528A1/en
Priority to US10/332,146 priority patent/US20040101824A1/en
Publication of WO2002003061A2 publication Critical patent/WO2002003061A2/de
Publication of WO2002003061A3 publication Critical patent/WO2002003061A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft Verfahren zur Identifizierung von als Arzneimittel für die Behandlung von Virusinfektionen geeigneten Stoffen, bzw. zur Prüfung ihrer Wirksamkeit. Weiter betrifft die vorliegende Erfindung die Anwendung eines entsprechenden Verfahrens zur Beobachtung des Infektionsweges oder/und -mechanismus von Viren in Zellen, insbesondere von Viren, welche als Genfähre zur Genexpression bzw. als Vektoren oder/und zur Gentherapie vorgesehen sind.
PCT/EP2001/007781 2000-07-06 2001-07-06 Verfahren zur identifizierung von die für behandlung von virusinfektionen geeigneten stoffen Ceased WO2002003061A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01955335A EP1297183A2 (de) 2000-07-06 2001-07-06 Verhahren zur identifizierung von für die behandlung von virusinfektionen geeigneten stoffen
CA002414786A CA2414786A1 (en) 2000-07-06 2001-07-06 Method for identifying substances which are suitable to be used for treating virus infections
AU2001277528A AU2001277528A1 (en) 2000-07-06 2001-07-06 Method for identifying substances which are suitable to be used for treating virus infections
US10/332,146 US20040101824A1 (en) 2000-07-06 2001-07-06 Method for identifying substances which are suitable to be used as medicaments for the treating virus infections or for testing the effectiveness of such substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10032859A DE10032859A1 (de) 2000-07-06 2000-07-06 Verfahren zum Erfassen von Viren
DE10032859.8 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003061A2 WO2002003061A2 (de) 2002-01-10
WO2002003061A3 true WO2002003061A3 (de) 2002-08-22

Family

ID=7648000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007781 Ceased WO2002003061A2 (de) 2000-07-06 2001-07-06 Verfahren zur identifizierung von die für behandlung von virusinfektionen geeigneten stoffen

Country Status (6)

Country Link
US (1) US20040101824A1 (de)
EP (1) EP1297183A2 (de)
AU (1) AU2001277528A1 (de)
CA (1) CA2414786A1 (de)
DE (1) DE10032859A1 (de)
WO (1) WO2002003061A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461836A1 (de) * 2017-09-28 2019-04-03 Universität zu Köln Mutierte kapsid proteine von adeno-assoziierten viren zur chemischen kopplung von liganden, nanopartikeln oder medikamenten über thioetherbindung und methode zu deren herstellung
CN111537480B (zh) * 2020-04-26 2023-05-02 中央民族大学 基于单分子全内反射荧光成像技术的病毒快速检测方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARTLETT JEFFREY S ET AL: "Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy.", NATURE MEDICINE, vol. 4, no. 5, May 1998 (1998-05-01), pages 635 - 637, XP002201152, ISSN: 1078-8956 *
BARTLETT JEFFREY S ET AL: "Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 6, March 2000 (2000-03-01), pages 2777 - 2785, XP002154341, ISSN: 0022-538X *
LEOPOLD PHILIP L ET AL: "Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells.", HUMAN GENE THERAPY, vol. 9, no. 3, 10 February 1998 (1998-02-10), pages 367 - 378, XP008004167, ISSN: 1043-0342 *
SEISENBERGER GEORG ET AL: "Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.", SCIENCE (WASHINGTON D C), vol. 294, no. 5548, 30 November 2001 (2001-11-30), pages 1929 - 1932, XP002201153, ISSN: 0036-8075 *
WEISS SHIMON: "Fluorescence spectroscopy of single biomolecules", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 283, no. 5408, 12 March 1999 (1999-03-12), pages 1676 - 1683, XP002171250, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
DE10032859A1 (de) 2002-01-17
CA2414786A1 (en) 2003-01-03
US20040101824A1 (en) 2004-05-27
WO2002003061A2 (de) 2002-01-10
EP1297183A2 (de) 2003-04-02
AU2001277528A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
EP1128832A4 (de) Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2002092006A3 (en) Nucleic acid-based compounds and methods of use thereof
WO2001090331A3 (en) C1 bacteriophage lytic system
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002006513A3 (en) A method for treating herpes viruses
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
WO2004085682A3 (de) Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
DE60132443D1 (de) In lebenden zielzellen
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
EP1558282A4 (de) Zusammensetzungen gegen krebs und infektionskrankheiten und anwendungsverfahren dafür
WO2002003061A3 (de) Verfahren zur identifizierung von die für behandlung von virusinfektionen geeigneten stoffen
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
WO2005092924A8 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
AU2003234342A1 (en) Ablated slam-dependent entry
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
FI965114A7 (fi) Farmaseuttinen koostumus virusinfektioiden sekä valinnaisesti tulehdusten estoon ja (tai) hoitoon sekä niiden hoitomenetelmä

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2414786

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001955335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001955335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10332146

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001955335

Country of ref document: EP